Phase III
Retrotope cited data from its Phase II/III trial of RT001 in patients with infantile neuroaxonal dystrophy and reported on a natural history study of INAD patients’ disease onset and progression.
Newly appointed CEO Rob Davis must find a way to balance Merck’s portfolio before investors get (even more) antsy. And he is looking to be aggressive.
AstraZeneca submitted data for an Emergency Use Authorization for AZD7442, a long-acting antibody combination from B-cells donated by patients who recovered from COVID-19.
The FDA granted the latest designation based on the Phase III DESTINY-Breast03 trial on adult patients diagnosed with unresectable or metastatic HER2-positive breast cancer.
Clinical trials have demonstrated that intermittent apomorphine injections provide rapid and effective relief from sudden, unexpected “off” periods brought on by primary Parkinson’s medicine, levodopa.
It was a busy week for clinical trial news. Here’s a look.
The Phase III trial on a potential treatment for mild-to-moderate COVID-19 symptoms by Merck and Ridgeback Biotherapeutics showed promise in preventing hospitalizations and death.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
Ferring Pharmaceuticals today announced positive results across all five of its prospective trials for a live biotherapeutic designed to reduce recurrent C. difficile infection (rCDI).
Indianapolis-based Eli Lilly presented data from two tirzepatide sub-studies at the 57th European Association for the Study of Diabetes (EASD) Annual Meeting.
PRESS RELEASES